2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Eloxx Pharmaceuticals reported a second-quarter 2026 net loss of $4.5 million, up from $1.9 million a year earlier, as research and development and general and administrative costs rose. The company completed a $66.0 million underwritten public offering in June 2026 and moved its listing to the Nasdaq Capital Market, and it says its cash will fund operations into mid-2028, which strengthens the balance sheet but adds new shares outstanding for existing holders.
Net loss for the quarter ended June 30, 2026 was $4.5 million, compared with $1.9 million for the same quarter of 2025.
The June 2026 underwritten offering had gross proceeds of $66.0 million and net proceeds of about $58.3 million.
Cash and cash equivalents were $62.0 million at June 30, 2026, which the company expects to fund operations into mid-2028.
Pixelworks reported second-quarter 2026 revenue of about $64,000, down from $159,000 a year earlier, while its net loss attributable to the company narrowed to $2.8 million from $6.7 million. Management expects third-quarter revenue to rise sequentially, but the company has not given formal guidance and says revenue will remain uneven until it scales.
Q2 2026 revenue was $64,000 versus $159,000 in Q2 2025; six-month revenue was $510,000.
Q2 2026 net loss attributable to Pixelworks was $2.8 million, compared with $6.7 million a year earlier. Six-month net income of $77.8 million reflects discontinued operations, including the sale of Pixelworks Shanghai, which closed January
Cash and cash equivalents were about $53 million at June 30, 2026, after $3.2 million of share repurchases in the quarter.
Management expects revenue to increase sequentially in Q3 2026 and plans cash operating expenses below $2.5 million per quarter for the rest of 2026.
The Eastern Company reported second quarter 2026 net sales of $61.8 million, down 12% from $70.2 million a year earlier, and adjusted EBITDA of $3.4 million, down about 49% from $6.7 million. GAAP diluted earnings per share rose to $0.94 from $0.33, but that figure includes a one-time, non-cash bargain purchase gain of $6.5 million tied to its June 1, 2026 acquisition of Sungear and Crown Precision. The filing gives no updated financial guidance.
Net sales fell 12% to $61.8 million, with lower truck mirror, returnable packaging and latch and handle shipments partly offset by $1.7 million of aerospace sales from the acquisition
Adjusted net income from continuing operations was $0.9 million, or $0.15 per diluted share, versus $0.57 a year earlier
GAAP net income from continuing operations was $5.6 million, or $0.94 per diluted share, including the $6.5 million bargain purchase gain
Backlog rose 45% year over year to $126.2 million; total debt increased $8.8 million to $41.7 million
Maze Therapeutics reported second-quarter 2026 results with a net loss of $44.7 million, or $0.76 per share, up from $33.7 million, or $0.77 per share, a year earlier. The company recognized $20.0 million in license revenue for the first half of 2026, tied to a first-quarter milestone under its Shionogi license, and ended June 30 with $494.9 million in cash, cash equivalents and marketable securities, which it expects will fund operations into 2029.
Q2 2026 net loss was $44.7 million ($0.76 per share), compared with $33.7 million ($0.77 per share) in Q2 2025; no license revenue was recognized in either quarter.
Six-month 2026 net loss was $68.9 million ($1.22 per share), compared with $66.5 million ($1.83 per share) in 2025, including $20.0 million of license revenue from a Shionogi milestone.
Q2 R&D expenses rose to $34.9 million from $28.1 million, and G&A expenses rose to $13.1 million from $8.4 million.
Cash position was $494.9 million at June 30, 2026, up from $360.0 million at December 31, 2025, following an April 2026 offering with gross proceeds of about $150 million.
Femasys Inc. closed a private placement on August 10, 2026, expected to bring in approximately $30.0 million in gross proceeds before offering expenses. The deal included common stock priced at $3.20 per share, plus warrants that could dilute existing holders, and gave the lead investor Nantahala Capital Management rights to appoint up to two board designees.
Purchase agreement dated August 7, 2026; closing occurred August 10, 2026, with expected gross proceeds of approximately $30.0 million
Common stock sold at $3.20 per share; 5,013,559 common shares and 4,361,440 pre-funded warrants issued, plus 18,749,998 accompanying warrants
Warrants exercisable at $2.95 per share; Milestone Warrants require U.S. revenue of at least $1,500,000 in a fiscal quarter and a stock price condition
Five company insiders, including the CEO and CFO, bought securities for an aggregate of approximately $134,000; resale registration statement due within 30 days of closing
Stran & Company reported second-quarter 2026 sales of $33.4 million, up 2.4% from a year earlier, but net income fell to $0.3 million from $0.6 million. For the first half, sales rose 5.4% to $64.6 million and net income rose to $1.1 million from $0.3 million. The filing gives no guidance, and the results are unaudited.
Q2 2026 sales $33.4 million, up 2.4%; gross profit $10.0 million, up 1.6%
Q2 net income $0.3 million vs. $0.6 million in Q2 2025; EBITDA $0.6 million vs. $0.9 million
Six months ended June 30, 2026: net income $1.1 million vs. $0.3 million; EBITDA $1.6 million vs. $0.7 million
Cash, cash equivalents and investments $12.6 million as of June 30, 2026; conference call on August 12, 2026 at 10:00 a.m. Eastern Time
AVITA Medical signed a Global Amendment with Stedical Scientific dated August 5, 2026, changing their PermeaDerm distribution and manufacturing agreements. The company's revenue share rises to 67% for sheet-form products and 80% for glove-form products, and it gains a right of first offer on expanding its territory to parts of Europe, the UK, and Australia for a $500,000 fee.
Company pays a $500,000 fee for a right of first offer and refusal on expanding exclusive distribution to all or part of the EU, UK, and/or Australia.
Company's revenue share from PermeaDerm sales rises to 67% for sheet form and 80% for glove form, with revenue-sharing increases tied to gross margin thresholds of 50% and 35%.
For 2026 the company must reach $1.0 million in total PermeaDerm revenue sharing payments, with 20% annual growth minimums through 2030; prior minimum payment requirements were waived.
Hyliion reported second-quarter 2026 revenue of $4.9 million, up from $1.5 million a year earlier, and a net loss of $13.9 million, compared with $13.4 million in the second quarter of 2025. The company raised its full-year 2026 revenue guidance to approximately $15 million from $10 million, while the wider net loss and continued cash use leave profitability further out of reach for shareholders.
Q2 2026 revenue was $4.9 million versus $1.5 million in Q2 2025; net loss was $13.9 million versus $13.4 million.
Full-year 2026 revenue guidance raised to approximately $15 million from $10 million.
Cash and investments were $132.4 million at June 30, 2026; year-end 2026 outlook is $115 million to $120 million, up from about $100 million.
The company cited a $41.7 million U.S. Navy contract awarded in the quarter.
Hour Loop reported second-quarter 2026 results, with net revenue up 25% year over year to $33.9 million while net income fell slightly to $1.1 million. Gross margin narrowed to 52.9% from 57.2%, and cash used in operating activities rose to $3.6 million from $0.9 million. The company reaffirmed its full-year 2026 net revenue and net income guidance, which matters to shareholders because it signals no change to the outlook despite weaker margins and cash flow.
Net revenues were $33.9 million, up from $27.1 million a year earlier; the company attributed the increase mainly to expanded inventory availability.
Net income was $1.1 million, or $0.03 per diluted share, compared with $1.2 million, or $0.04 per diluted share, in the prior-year quarter.
Gross margin fell to 52.9% from 57.2%, and cash used in operating activities was $3.6 million versus $0.9 million a year earlier.
Full-year 2026 guidance was reaffirmed: net revenue of $143.0 million to $163.0 million and net income of $0.75 million to $1.5 million.
RideNow Group reported second-quarter 2026 results for the period ended June 30, 2026. Total revenue fell 1.0% to $296.8 million, while net income improved to $6.5 million from a net loss of $32.2 million a year earlier, which included a $34.0 million franchise rights impairment charge. The board also adopted Third Amended and Restated Bylaws, effective August 5, 2026, covering virtual stockholder meetings, universal proxy rules, and forum selection.
Total revenue decreased 1.0% to $296.8 million from $299.9 million, which the company attributes to store consolidation and the end of its transportation services in December 2025.
Gross profit rose 1.1% to $84.8 million, and same store powersports revenue was up 3.0%.
Net income was $6.5 million, compared with a net loss of $32.2 million in the second quarter of 2025. Adjusted EBITDA rose 19.2% to $20.5 million.
Bylaws effective August 5, 2026 authorize virtual meetings and electronic notice, add Rule 14a-19 universal proxy requirements, and designate Nevada and federal courts as exclusive forums.
Lumentum reported fourth-quarter fiscal 2026 net revenue of $1.01 billion, up from $480.7 million a year earlier, but a $7.8 billion non-cash loss on debt extinguishment from equitizing convertible notes drove a GAAP net loss of $7.2 billion, or $84.65 per diluted share. The company guided first-quarter fiscal 2027 net revenue to $1.225 billion to $1.275 billion, with non-GAAP diluted EPS of $4.05 to $4.35.
Q4 fiscal 2026 net revenue was $1.01 billion, up 109.3% year over year and 24.5% from the third quarter's $808.4 million.
Q4 GAAP net loss was $7.2 billion ($84.65 per diluted share), driven by a one-time, non-cash loss on debt extinguishment of $7.8 billion.
Q4 non-GAAP net income was $326.3 million, or $3.23 per diluted share, versus $0.88 a year earlier.
Q1 fiscal 2027 guidance: net revenue of $1.225 billion to $1.275 billion and non-GAAP operating margin of 39.5% to 40.5%.
Seer reported second-quarter 2026 revenue of $3.1 million, down 23% from $4.1 million a year earlier, which the company attributed to academic and government funding pressure and longer sales cycles. The net loss narrowed to $16.9 million from $19.4 million as operating expenses fell 19%, and Seer reaffirmed its full-year 2026 revenue guidance of $16 million to $18 million. Shareholders get lower sales offset partly by lower costs, with cash, cash equivalents and investments of $209.5 million at June 30, 2026.
Q2 2026 revenue was $3.1 million, down 23% from $4.1 million in Q2 2025
Operating expenses were $18.3 million, down 19% from $22.6 million
Net loss per share was $0.31, compared with $0.33 a year earlier
Full-year 2026 revenue guidance of $16 million to $18 million was reaffirmed
Mobia Medical reported second-quarter 2026 revenue of $13.5 million, up 102% from a year earlier, and gave full-year 2026 revenue guidance of $54.0 million to $56.0 million. Operating expenses rose 83% to $29.2 million, and the net loss widened to $21.0 million from $10.5 million, so revenue growth came with a larger loss for shareholders.
Q2 2026 revenue $13.5 million vs. $6.7 million in Q2 2025; gross margin 83.2% vs. 82.3%
Net loss $21.0 million vs. $10.5 million a year earlier; loss per share $1.10 vs. $12.44, reflecting more weighted-average shares after the IPO
Full-year 2026 revenue outlook $54.0 million to $56.0 million, growth of 69% to 75%
Cash and cash equivalents $177.1 million at June 30, 2026, including about $134.0 million net IPO proceeds
National CineMedia reported fiscal second quarter 2026 revenue of $58.4 million, up 12.7%, while its operating loss widened and its net loss narrowed to $9.9 million. The company also agreed on August 10, 2026 to acquire Captivate Holdings for an enterprise value of $275.0 million, paused its quarterly dividend, and gave no forward outlook, which matters to shareholders because it adds significant debt and removes near-term guidance.
Q2 revenue rose 12.7% to $58.4 million from $51.8 million; operating loss widened to $12.8 million from $12.0 million.
Net loss narrowed to $9.9 million, or $0.11 per diluted share, from $10.7 million, or $0.11 per diluted share, a year earlier.
Captivate acquisition: enterprise value of $275.0 million, funded by $275.0 million of new committed term debt; expected to close in the second half of 2026.
Quarterly dividend paused due to the proposed acquisition and expected leverage at closing; no forward outlook provided.
Cardiff Oncology reported a second-quarter 2026 net loss of $9.2 million, or $0.14 per share, down from $13.9 million, or $0.21 per share, a year earlier, as research and development spending fell. Royalty revenue slipped to $104,000 from $121,000, and cash, cash equivalents and short-term investments were $34.5 million at June 30, 2026, before a $10 million registered direct offering completed after quarter end. The company says its cash resources fund operations into the third quarter of 2027, and it plans to start a Phase 3 trial in the first quarter of 2027 subject to securing additional financing.
Q2 2026 net loss was $9.2 million ($0.14 per share) versus $13.9 million ($0.21 per share) in Q2 2025.
Royalty revenue was $104,000 versus $121,000; total operating expenses were $9.7 million versus $14.9 million.
Cash, cash equivalents and short-term investments were $34.5 million at June 30, 2026, excluding the $10 million offering completed after quarter end.
Cash resources are expected to fund operations into the third quarter of 2027; Phase 3 start planned for Q1 2027, subject to additional financing.
Quantinuum reported second-quarter 2026 revenue of $8 million, up 279% from $2 million a year earlier, while its GAAP net loss rose to $597 million from $57 million. The company also set its first formal public-company guidance, expecting 2026 revenue of $28 million to $32 million, and announced a multi-year partnership with Oracle to offer its Helios quantum computer on Oracle Cloud Infrastructure.
Q2 2026 GAAP net loss was $597 million, or $1.93 per Class A share, compared with a net loss of $57 million a year earlier.
Adjusted EBITDA loss was $68 million, compared with $43 million in the prior-year quarter.
2026 revenue guidance is $28 million to $32 million, the company's first formal guidance as a public company.
Cash and short-term investments were $2.1 billion as of June 30, 2026, after an IPO that raised $1.7 billion in gross proceeds.
Codexis reported second-quarter 2026 revenue of $14.9 million, down from $15.3 million a year earlier, while its net loss narrowed to $12.0 million, or $0.13 per share, from $13.3 million, or $0.16 per share. The company reiterated its full-year 2026 revenue guidance of $72 million to $76 million and said a July equity raise brought in about $25 million in net proceeds, for proforma cash of about $80 million.
Q2 2026 total revenues were $14.9 million, versus $15.3 million in Q2 2025, mainly due to lower research and development revenue.
Net loss was $12.0 million, or $0.13 per share, compared with $13.3 million, or $0.16 per share, a year earlier.
Full-year 2026 total revenue guidance of $72 million to $76 million was reiterated, not changed.
An equity financing completed in July raised about $25 million in net proceeds; proforma cash is about $80 million.
CoreWeave reported second-quarter 2026 revenue of $2,575 million, up from $1,212 million a year earlier, and a $626 million net loss, up from $290 million. Operating income swung to a $49 million loss from a $19 million profit, and the company ended the quarter with approximately $104 billion in revenue backlog. The filing contains no new guidance; management said it would provide forward-looking guidance on the earnings call.
Q2 2026 revenue was $2,575 million versus $1,212 million in Q2 2025.
Net loss was $626 million, or $1.14 per share, compared with $290 million, or $0.60 per share, a year earlier.
Operating loss was $49 million, compared with operating income of $19 million in Q2 2025.
Revenue backlog was approximately $104 billion as of June 30, 2026, excluding more than $25 billion of net new commitments added in early Q3.
Intelligent Protection Management Corp. reported second-quarter 2026 revenue of $6.5 million, up 13% from a year earlier, driven by a 64% rise in procurement revenue tied to AI-related equipment sales. Net loss widened to $1.4 million from $1.1 million, and the company said supply chain constraints delayed recognition of some booked orders. Higher sales came with larger losses, and the company reported $7.5 million in cash and no long-term debt at June 30, 2026.
Q2 2026 total revenue was $6.5 million, up 12.9% from $5.7 million in Q2 2025.
Q2 2026 net loss was $1.4 million, compared with $1.1 million a year earlier.
Six-month revenue was $12.8 million, up 14.0%, while six-month net loss was $2.0 million versus $0.2 million.
Procurement revenue rose 64.0% to $2.0 million; cash and cash equivalents totaled $7.5 million at June 30, 2026.
Comscore said it will reduce its workforce and other corporate costs under a realignment plan authorized by its board on August 6, 2026, with estimated one-time costs of $7 million to $9 million. The company expects $20 million to $25 million in annual run-rate cost savings, and its CEO and CFO agreed to salary cuts and other pay changes, while the chief commercial officer will move to an advisory role until December 1, 2026. For shareholders, the expected savings must be weighed against the one-time charges and the risk that execution costs or unintended effects exceed expectations.
The realignment plan was authorized by the board on August 6, 2026 and announced on August 11, 2026.
Estimated one-time costs are $7 million to $9 million, including $6 million to $8 million in cash severance and termination benefits.
Expected annual run-rate cost savings are $20 million to $25 million, with implementation substantially complete in the third quarter of 2027.
CEO Matt McLaughlin's base salary falls from $625,000 to $500,000 effective October 1, 2026; CFO Mary Margaret Curry's falls 10% to $360,000.
SES AI reported second-quarter 2026 revenue of $5.1 million, up from $3.5 million a year earlier but down from $6.7 million in the first quarter, and reaffirmed its 2026 revenue guidance of $30 million to $35 million. GAAP net loss was $17.9 million, or $0.05 per share, narrower than a year earlier but wider than the $12.1 million loss in the first quarter, and the company reported about $163 million in cash, cash equivalents and short-term investments. The board also appointed Paul Diemer as a Class II director effective August 6, 2026.
Q2 2026 revenue was $5.1 million, versus $3.5 million in Q2 2025 and $6.7 million in Q1 2026
GAAP gross margin was 22.6%, up from 18.1% in Q1 2026
GAAP net loss was $17.9 million ($0.05 per share), versus $22.7 million ($0.07 per share) in Q2 2025 and $12.1 million in Q1 2026
Board appointed Paul Diemer as a Class II director effective August 6, 2026, with a term expiring at the 2027 annual meeting
National CineMedia's subsidiary agreed on August 10, 2026 to acquire Captivate Holdings, LLC, a digital video elevator and lobby advertising operator, for an enterprise value of $275.0 million, funded with new committed term debt. The company said it is pausing its dividend and share repurchase programs so free cash flow can go toward debt reduction, and it expects closing in the second half of 2026.
Enterprise value of $275.0 million, payable in cash, subject to customary purchase price adjustments; the Company guaranteed the Buyer's obligations
Financing: $275.0 million senior secured term loan and $25.0 million revolving facility, with a maximum Total Net Leverage Ratio of 5.00:1.00 stepping down over time; the company expects net leverage of approximately 3.9x at close
Captivate's 2025 revenue was approximately $64 million and Adjusted EBITDA approximately $19 million, according to the press release
Dividend and share repurchase programs are paused; closing is expected in the second half of 2026, subject to conditions including HSR waiting period expiration
LENZ Therapeutics reported second-quarter 2026 results for the quarter ended June 30, 2026, with total revenue of $5.5 million, up from $5.0 million a year earlier. The net loss widened to $31.9 million, or $1.02 per share, from $14.9 million, or $0.53 per share, as selling, general and administrative expenses rose sharply to support the VIZZ launch. The filing does not include financial guidance, and the company reported $220.0 million in cash, cash equivalents and marketable securities.
Total revenue of $5.5 million for Q2 2026, including $1.7 million in product sales and $3.8 million in license revenue, versus $5.0 million in license revenue in Q2 2025
Net loss of $31.9 million, or $1.02 per share, versus $14.9 million, or $0.53 per share, in Q2 2025
SG&A expenses rose to $39.4 million from $12.8 million, driven by launch investment, marketing and headcount growth
Cash, cash equivalents and marketable securities totaled $220.0 million as of June 30, 2026
American Vanguard reported unaudited results for the second quarter and first half of 2026. Second-quarter net sales fell 10% to $116.8 million and the company posted a net loss of $9.9 million, or $0.34 per share, compared with a net loss of $0.8 million, or $0.03 per share, a year earlier. For the first half, adjusted EBITDA rose to $16.9 million from $14.0 million, but the net loss widened to $14.0 million, and the company reaffirmed its full-year outlook.
Q2 2026 net sales were $116.8 million vs. $129.3 million in Q2 2025; operating loss was $0.3 million vs. operating income of $4.4 million.
Q2 adjusted EBITDA was $6.6 million vs. $11.0 million; first-half adjusted EBITDA was $16.9 million vs. $14.0 million.
First-half net loss was $14.0 million, or $0.49 per share, vs. $9.3 million, or $0.33 per share, a year earlier.
Full-year outlook reaffirmed: adjusted EBITDA of $44 million to $48 million on sales of $530 million to $550 million.
Firefly Aerospace reported second-quarter 2026 revenue of $117.7 million, up from $15.5 million a year earlier, and expects full-year 2026 revenue of $420 million to $450 million. The net loss widened to $92.3 million from $63.8 million, while the per-share loss narrowed to $0.57 from $5.78 as the weighted-average share count rose to 161.8 million from 13.9 million. For shareholders, the revenue growth is offset by a larger loss and higher cash use.
Second-quarter revenue was $117.7 million, versus $15.5 million in the same quarter of 2025.
Net loss was $92.3 million, versus $63.8 million a year earlier; net loss per share was $0.57, versus $5.78.
Firefly expects 2026 full-year revenue of $420 million to $450 million.
Free cash flow was negative $106.3 million in the quarter, and cash and cash equivalents were $459.8 million at June 30, 2026.
Gladstone Land reported a second-quarter 2026 net loss of $8.5 million, wider than the $7.9 million loss a year earlier, after a non-cash impairment charge of about $4.2 million on four Arizona farms. Total operating revenues rose 3.2% to $12.7 million, and the loss attributable to common stockholders narrowed to $0.32 per share from $0.38. The company said a substantial majority of its 2026 revenue is expected in the fourth quarter, when participation rents are generally recognized.
Total operating revenues were $12.7 million, up from $12.3 million, a 3.2% increase.
Net loss attributable to common stockholders was $13.5 million, or $0.32 per share, versus $13.9 million, or $0.38 per share, a year earlier.
AFFO was a loss of $1.6 million, or $0.04 per share, compared with a loss of $3.5 million, or $0.10 per share, in the prior-year quarter.
Monthly common distributions declared were $0.0467 per share for each of July, August and September, totaling $0.1401 for the quarter.
NextNav reported second-quarter 2026 results with revenue of $1.15 million, down from $1.20 million a year earlier, and an operating loss that widened to $20.2 million from $17.2 million. The net loss narrowed to $33.8 million from $63.2 million, helped by a $21.4 million debt extinguishment gain, and the company's $190 million convertible notes were converted into about 15.2 million shares, eliminating that debt.
Q2 2026 revenue was $1.15 million versus $1.20 million in Q2 2025; operating loss was $20.2 million versus $17.2 million.
Net loss was $33.8 million, or $0.24 per share, versus $63.2 million, or $0.48 per share, a year earlier.
Public warrant exercises generated about $169.5 million of gross proceeds; the $190 million convertible notes converted into about 15.2 million shares.
Total available liquidity was about $298 million as of June 30, 2026, including $69.3 million of warrant proceeds collected July 1, 2026.
Absci reported second-quarter 2026 results with revenue of $0.3 million, down from $0.6 million a year earlier, and a net loss of $33.2 million, up from $30.6 million. The company said its cash, cash equivalents, and marketable securities of $201.1 million, which include $93.6 million of net offering proceeds, are now expected to fund operations into the second half of 2028, which lessens near-term funding pressure for shareholders.
Revenue was $0.3 million for the quarter ended June 30, 2026, compared with $0.6 million a year earlier.
Net loss was $33.2 million, or $0.21 per share, compared with $30.6 million, or $0.24 per share, a year earlier.
Completed a $100 million underwritten offering that included a $40 million strategic equity investment from Eli Lilly & Company.
Cash and marketable securities were $201.1 million as of June 30, 2026, versus $125.7 million as of March 31, 2026.
Anterix reported first quarter fiscal 2027 results for the three months ended June 30, 2026. Spectrum revenue rose to $2.0 million from $1.4 million a year earlier, but net income fell to $240,000, or $0.01 per diluted share, from $25.2 million, or $1.35, as the prior-year period included a $33.9 million gain on exchange of intangible assets. The company reported no debt and $116.0 million in cash at June 30, 2026.
Net income was $240,000 ($0.01 per diluted share), compared with $25,180,000 ($1.35 per diluted share) a year earlier.
Cash and cash equivalents were $116.0 million at June 30, 2026, with no debt; $226.7 million remained under the share repurchase program, and there was no repurchase activity in the quarter.
Management will hold a business update call at 9:00 A.M. ET on August 12, 2026.
Snail, Inc. reported second-quarter 2026 revenue of $19.7 million, down from $22.2 million a year earlier, as lower ARK: Survival Ascended sales outweighed Bellwright gains. The net loss narrowed to $3.0 million from $16.6 million, mainly because of a $14.0 million smaller income tax provision, so shareholders see a smaller loss on lower sales.
Q2 net revenues were $19.7 million vs. $22.2 million; ARK: Survival Ascended sales fell $4.2 million, and Bellwright added $1.5 million.
Q2 net loss was $3.0 million vs. $16.6 million; the prior-year quarter included a $13.9 million income tax provision.
Six-month net revenues rose 11.1% to $47.0 million; six-month net loss was $0.9 million vs. $18.5 million.
Unrestricted cash was $13.3 million as of June 30, 2026, up from $8.6 million on December 31, 2025.
Bolt Biotherapeutics reported second-quarter 2026 collaboration revenue of $5,000, down from $1.8 million a year earlier, while its net loss narrowed to $7.7 million from $8.6 million on lower research and general and administrative expenses. Cash, cash equivalents and marketable securities were $18.1 million at June 30, 2026, which the company expects to fund operations into the first quarter of 2027, and it said initial clinical data for its lead candidate BDC-4182 is expected with third-quarter 2026 results.
Collaboration revenue was $5,000 for Q2 2026, versus $1.8 million in Q2 2025
Net loss was $7.7 million, or $4.57 per share, versus $8.6 million, or $4.46 per share, a year earlier
Cash and marketable securities of $18.1 million as of June 30, 2026, expected to fund operations into 1Q 2027
Initial BDC-4182 clinical data expected with 3Q 2026 results; the rest of the pipeline is on hold
Smart Sand reported second-quarter 2026 revenue of $115.1 million, up from $93.1 million in the first quarter and $85.8 million a year earlier, and said it expects 2026 sales volumes to rise 10% to 20% from 2025. Net income was $10.2 million, down from $21.4 million a year earlier but up from a $3.9 million loss in the first quarter. The company also said CFO Lee Beckelman will step down effective January 1, 2027, with General Counsel James Young named as his successor; Young's compensation has not yet been determined.
Q2 2026 revenue was $115.1 million, versus $93.1 million in Q1 2026 and $85.8 million in Q2 2025.
Q2 2026 net income was $10.2 million, or $0.26 per basic share, versus $21.4 million, or $0.55 per basic share, in Q2 2025.
Adjusted EBITDA was $18.7 million, and free cash flow was $(1.4) million in Q2 2026.
Lee Beckelman will leave the CFO role effective January 1, 2027; James Young, currently General Counsel, is named successor, and Beckelman will remain as an advisor through May 31, 2030.
Energy Focus reported second-quarter 2026 net sales of $3.7 million, up 228% from $1.1 million a year earlier, driven mainly by initial shipments to a new Australian customer and higher military maritime product sales. Gross margin turned negative at (6.8)%, and the net loss widened to $0.9 million, or $(0.14) per share, from $0.2 million, or $(0.04) per share, a year earlier. The release also cites the need for additional financing and substantial doubt about the company's ability to continue as a going concern.
Net sales were $3.7 million in Q2 2026, up from $1.1 million in Q2 2025; commercial sales rose $1.5 million on initial shipments to a new Australian customer.
Gross margin was (6.8)% versus 12.9% in Q2 2025, which the company attributed mainly to higher inventory reserves.
Net loss was $0.9 million, or $(0.14) per share, compared with $0.2 million, or $(0.04) per share, in Q2 2025.
Cash was $1.1 million at June 30, 2026, with $911 thousand in short-term borrowings outstanding; a May 2026 private placement with Euka Power Japan Co., Ltd. raised about $250,000 at $3.80 per share.
Mereo BioPharma reported second-quarter 2026 results with a net loss of $7.0 million, down from $14.6 million a year earlier, and revenue of zero versus $0.5 million in the prior-year quarter. The company also signed an option and license agreement with Sentynl Therapeutics for alvelestat, and said its cash of $30.1 million should fund operations into late 2027, while setrusumab's Phase 3 studies missed their primary endpoints.
Q2 2026 net loss was $7.0 million, compared with $14.6 million in Q2 2025; revenue was zero versus $0.5 million a year earlier.
Cash and cash equivalents were $30.1 million at June 30, 2026, down from $41.0 million at December 31, 2025, and are expected to fund operations into late 2027.
Sentynl can exercise an option to license alvelestat; on exercise Mereo would be eligible for $40 million in upfront and R&D payments and up to $435 million in milestones.
Orbit and Cosmic Phase 3 studies of setrusumab did not meet the primary fracture-rate endpoints; Mereo and Ultragenyx expect a regulatory path update by year-end 2026.
Enviri reported a second-quarter 2026 GAAP loss from continuing operations of $297 million, or $10.70 per diluted share, driven by charges for exiting two European Harsco Rail ETO contracts and transaction-related items tied to the Clean Earth sale and spin-off. Adjusted EBITDA rose to $34 million from $27 million, and the company reaffirmed its 2026 Adjusted EBITDA outlook for Harsco Environmental and Harsco Rail.
GAAP loss from continuing operations was $297 million, or $10.70 per diluted share, versus a loss of $45 million, or $1.70 per share, in Q2 2025.
Adjusted EBITDA was $34 million, up from $27 million a year earlier; adjusted diluted loss per share was $0.63, compared with $0.84.
Reported revenues were $187 million, down from $316 million, but $324 million excluding the Rail contract exit adjustments, a 2% increase.
The company reaffirmed 2026 Adjusted EBITDA guidance of $170 million to $180 million for Harsco Environmental and $(26) million to $(19) million for Harsco Rail.
Neuronetics reported second-quarter 2026 revenue of $41.6 million, up 9.1% from a year earlier, driven by Greenbrook clinic revenue. Net loss narrowed to $3.4 million from $10.1 million, but the company trimmed the top end of its full-year 2026 revenue guidance and appointed a new chief financial officer.
Total revenue $41.6 million, up 9.1%; Greenbrook revenue $26.9 million, up 16.8%
Net loss $3.4 million, or $0.05 per share, versus $10.1 million, or $0.15 per share, a year earlier
FY2026 revenue guidance $160 million to $164 million, versus prior $160 million to $166 million
Nir Naor appointed Executive Vice President and Chief Financial Officer
Bicara Therapeutics said Ryan Cohlhepp, its President and Chief Operating Officer, will succeed Claire Mazumdar as Chief Executive Officer effective January 1, 2027, and Jenn Larson will become Chief Financial Officer effective August 12, 2026. The company also reported a second quarter 2026 net loss of $55.4 million, up from $27.4 million a year earlier, while cash, cash equivalents and marketable securities rose to $497.3 million.
Ryan Cohlhepp will become CEO effective January 1, 2027; Claire Mazumdar will become Vice Chair of the Board and Strategic Advisor.
Jenn Larson, CPA, appointed Chief Financial Officer effective August 12, 2026, succeeding Ivan Hyep.
Q2 2026 net loss was $55.4 million versus $27.4 million in Q2 2025; R&D expenses were $45.8 million versus $24.8 million.
Cash, cash equivalents and marketable securities were $497.3 million at June 30, 2026, which the company expects to fund operations into the first half of 2029.
Neurogene reported second quarter 2026 results, with a net loss of $34.5 million versus $22.0 million a year earlier, driven by higher R&D and G&A expenses including a one-time stock-based compensation catch-up charge. The company also said an oversubscribed public offering of about $144 million gross proceeds extends its cash runway into the first quarter of 2029, and it reported updated Phase 1/2 data for NGN-401 in Rett syndrome.
Net loss was $34.5 million for the quarter ended June 30, 2026, compared with $22.0 million a year earlier.
R&D expenses rose to $25.5 million from $19.4 million; G&A expenses rose to $11.2 million from $6.7 million.
Pro forma cash, cash equivalents and short-term investments were about $360.2 million, including about $134.8 million of net proceeds from the July 2, 2026 offering.
Topline Embolden registrational data are expected in the second half of 2027.
DPC Holdings reported record second-quarter 2026 revenue of $269 million, up 34%, and adjusted EBITDA of $48 million, up 33%, with the company also initiating full-year 2026 guidance. GAAP net loss widened to $131 million from $49 million, which the company attributed mainly to its Management Incentive Plan accrual, IPO expenses and a new incentive share scheme. Shareholders see strong top-line growth alongside a much larger GAAP loss.
Q2 2026 revenue $269 million, up 34% from $201 million; adjusted EBITDA $48 million, up 33%, margin 17.8%
Net loss $131 million (EPS of ($1.14)) versus $49 million (EPS of ($0.44)) in Q2 2025
Adjusted net income $6 million versus a $11 million loss a year earlier
Full-year 2026 guidance: revenue $1.00 billion to $1.04 billion; adjusted EBITDA $182 million to $187 million
Upstream Bio reported second-quarter 2026 results with a net loss of $39.7 million, compared with $40.0 million a year earlier, and collaboration revenue of $773,000, down from $937,000. The company said it remains on track to start Phase 3 trials of verekitug in severe asthma and CRSwNP in the first quarter of 2027, and that its cash runway extends through 2027, which matters to shareholders as the company funds its clinical program.
Net loss of $39.7 million for Q2 2026 versus $40.0 million in Q2 2025
Research and development expenses of $36.1 million, down from $37.9 million
Cash, cash equivalents and short-term investments of $261.3 million as of June 30, 2026, expected to fund operations through 2027
Phase 3 trials in severe asthma and CRSwNP targeted to begin in Q1 2027; COPD Phase 2 data expected in second half of 2027
Middleby reported second-quarter 2026 net sales of $876 million, up 9.9%, and adjusted EBITDA of $193 million, up from $182 million a year earlier. GAAP diluted EPS from continuing operations fell to $1.20 from $1.91, which the filing ties to a $28.9 million equity loss from an affiliate and $14 million of strategic transaction costs, while adjusted EPS rose to $2.35 from $2.20. The company said it raised its full-year 2026 guidance after completing the Food Processing spin-off on July 6, 2026.
Q2 2026 net sales of $875.5 million, up 9.9% (6.4% organic); Commercial Foodservice organic growth of 8.3%
Diluted GAAP EPS from continuing operations of $1.20 versus $1.91; adjusted EPS of $2.35 versus $2.20
Full-year 2026 adjusted EPS guidance of $6.73-$6.89 and net sales of $2.48-$2.53 billion, excluding Food Processing and Residential
Company repurchased 1.4 million shares in Q2 2026 and 3.8 million shares year to date
Harvard Bioscience furnished an August 2026 investor presentation under Regulation FD showing second-quarter 2026 revenue of $22.7 million, up 11% from $20.5 million a year earlier. The company raised its full-year 2026 revenue growth guidance to 3% to 5% from 2% to 4%, but lowered its adjusted gross margin guidance to 57% to 59% from 58% to 60%. GAAP net loss widened to $2.9 million from $2.3 million, while adjusted EBITDA rose to $1.7 million from $1.5 million.
Q2 2026 revenue of $22.7 million, up from $20.5 million in Q2 2025
GAAP net loss of $2.9 million, compared with $2.3 million a year earlier
Adjusted EBITDA of $1.7 million, up from $1.5 million; adjusted EBITDA growth guidance for FY26 maintained at 6% to 10%
Q3 2026 revenue guidance of $21.0 million to $22.6 million
Harvard Bioscience reported second quarter 2026 revenue of $22.7 million, up 11% from $20.5 million a year earlier, and raised its full-year 2026 revenue growth guidance to 3% to 5%. The company's GAAP net loss widened to $2.9 million from $2.3 million, so the sales gain came with a larger loss for shareholders.
Q2 2026 revenue of $22.7 million vs. $20.5 million in Q2 2025; foreign currency added about 1%
Q2 2026 net loss of $2.9 million vs. $2.3 million in Q2 2025; adjusted EBITDA rose to $1.7 million from $1.5 million
Full-year 2026 revenue growth guidance raised to 3% to 5%; adjusted gross margin target lowered to 57% to 59%
Third quarter 2026 revenue guidance of $21.0 million to $22.6 million
Janus International reported second-quarter 2026 revenue of $233.5 million, up 2.4% year over year, while net income fell to $10.7 million from $20.7 million and adjusted EBITDA fell 18.0% to $40.2 million. The company also updated its full-year 2026 outlook, with total revenue guided to $925 million to $945 million and adjusted EBITDA to $150 million to $170 million, and the CEO said results came in slightly below company expectations.
Net income was $10.7 million, or $0.08 per diluted share, versus $20.7 million, or $0.15, a year earlier.
Adjusted EBITDA was $40.2 million, down 18.0%, with an adjusted EBITDA margin of 17.2%, down about 430 basis points.
Full-year 2026 guidance: total revenue of $925 million to $945 million and adjusted EBITDA of $150 million to $170 million.
Nokē Smart Entry System installed units reached 501,000 at quarter end, up 22.5% year over year.
Kardigan, a clinical-stage company with no reported revenue, posted a second-quarter 2026 net loss of $116.2 million, up from $57.4 million a year earlier, mainly due to higher research and development costs. The loss per share was $4.61, compared with $4.64 a year earlier, as the share count rose after its June initial public offering. Cash, cash equivalents and investments were $660.7 million at June 30, 2026.
Net loss was $116.2 million for the quarter ended June 30, 2026, versus $57.4 million a year earlier.
Research and development expenses rose to $56.4 million from $35.8 million, driven by clinical trial costs and headcount.
A $43.5 million change in fair value of contingent milestone liabilities was included in operating expenses.
Cash, cash equivalents and investments were $660.7 million at June 30, 2026, after net proceeds from the June 2026 IPO.
Shattuck Labs reported no revenue for the quarter ended June 30, 2026, and a net loss of $15.2 million, up from $12.5 million a year earlier. Loss per share narrowed to $0.12 from $0.24, while the weighted-average share count rose to about 129.8 million from about 51.0 million. Cash, cash equivalents and short-term investments were $208.3 million, which the company says should fund operations into 2029.
Net loss was $15.2 million, or $0.12 per share, for Q2 2026, versus $12.5 million, or $0.24 per share, for Q2 2025.
R&D expenses rose to $11.7 million from $8.7 million; G&A expenses were $4.5 million versus $4.4 million.
Cash and short-term investments were $208.3 million at June 30, 2026, versus $50.5 million a year earlier.
The RECEPTIVE-CD1 Phase 2b trial of SL-325 in Crohn's disease is expected to start in Q3 2026; the company also cites a $86.2 million underwritten offering and $57.1 million from warrant exercises.
Ampco-Pittsburgh reported second quarter 2026 net income attributable to the company of $1.5 million, or $0.07 per share, compared with a net loss of $7.3 million, or $0.36 per share, a year earlier. Net sales declined to $102.9 million from $113.1 million, mainly due to the closure of the U.K. cast roll facility, while backlog rose to $385.4 million.
Net income attributable to Ampco was $1.5 million, or $0.07 per share, versus a net loss of $7.3 million, or $0.36 per share, in the prior-year quarter, which included $6.75 million of U.K. exit costs.
Net sales were $102.9 million versus $113.1 million, reflecting the closure of the U.K. cast roll facility included in prior-year results.
Adjusted EBITDA rose 22% to $9.8 million, and backlog increased $39.9 million sequentially to $385.4 million as of June 30, 2026.
Free cash flow was $(5.5) million versus $(3.8) million a year earlier; net debt was $130.5 million at June 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.